|
|
Aptalis Pharma Begins Promotion of RECTIV™ to Physicians in the U.S.
|
|
|
Aptalis Pharma Announces FDA Approval of ULTRESA(TM) Pancrelipase Delayed Release Capsules and VIOKACE(TM) Pancrelipase Tablets
|
Aptalis Pharma Begins Promotion of RECTIV™ to Physicians in the U.S.
BRIDGEWATER, NJ--(Marketwire – March 16, 2012) - Aptalis Pharma, a global specialty pharmaceutical company focused on gastrointestinal diseases and cystic fibrosis, today announced that it has begun promoting RECTIV™ (nitroglycerin) Ointment 0.4 % to physicians in the U.S. RECTIV is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe pain associated with chronic anal fissure....
